Analyst Jason Gerberry works at BAML and is focused on the Healthcare sector with 482 price targets and ratings documented since 2014 spanning on 36 stocks. Previously, Jason Gerberry worked at LEERINK. Analyst's average stock valuation to be materialised ratio is 61.56% with an average time for price targets to be met of 189.92 days.
Most recent stock forecast was given on FGEN, FibroGen, Inc at 05-Jan-2023.
Jason Gerberry best performing recommendations are on KRTX (KARUNA THERAPEUTICS, INC).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS, INC) at 8/9/2022. The price target of $261 was fulfilled within 2 days with a profit of $32.55 (14.25%) receiving and performance score of 71.24.
Average potential price target upside
Currently, out of the existing stock ratings of Jason Gerberry - 20632 which are a Buy (66.72%), 7261 which are a Hold (23.48%), 3029 which are a Sell (9.8%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
172
$13.75 (8.69%)
166
28 days ago
23/24 (95.83%)
$22.93 (27.45%)
344
Sell
153
$-5.25 (-3.32%)
135
1 months 19 days ago
20/20 (100%)
$19.5 (30.42%)
515
Buy
163
$4.75 (3.00%)
157
1 months 19 days ago
34/35 (97.14%)
$24.2 (28.52%)
414
Sell
153
$-5.25 (-3.32%)
92
1 months 19 days ago
6/6 (100%)
$25.57 (55.74%)
574
Hold
154
$-4.25 (-2.69%)
157
1 months 19 days ago
4/4 (100%)
$15.03 (18.69%)
198
